Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
- None.
- None.
Insights
The partnership between Danaher Corporation and the Innovative Genomics Institute (IGI) is a significant step in the advancement of gene-editing therapies, particularly for rare diseases. The collaborative effort to create a scalable platform for CRISPR-based treatments addresses a critical gap in the current biotech landscape. Rare diseases, often orphaned by larger pharmaceutical companies due to the high costs and low financial returns, represent a significant unmet medical need. The development of a 'CRISPR cures cookbook' could revolutionize the way therapies for these conditions are developed, potentially reducing both time and cost.
From a biotechnology perspective, the creation of a unified research, development and regulatory framework could streamline the process of bringing gene-editing therapies to market. This is especially pertinent given the complexity of navigating the current regulatory environment for such innovative treatments. By potentially simplifying this process, Danaher and IGI could accelerate the availability of new therapies for patients, which in turn could have a positive impact on Danaher's business performance as they tap into a new segment of the healthcare market.
The strategic alliance between Danaher and IGI holds substantial promise for investor consideration. The focus on developing a platform for rapid deployment of CRISPR gene-editing therapies could lead to significant cost reductions in the drug development process. This would not only be beneficial for patients but could also enhance the profitability of Danaher's life sciences segment. Furthermore, the involvement of Nobel laureate Jennifer Doudna provides a strong endorsement of the scientific credibility of the initiative, which may foster investor confidence.
Investors should also note the potential for this collaboration to open up new revenue streams for Danaher, particularly if the platform approach proves successful and is adopted widely for other diseases. The ability to rapidly prototype and scale treatments for a variety of conditions could position Danaher as a leader in the gene-editing space, potentially leading to long-term growth and an enhanced competitive advantage in the market.
The gene-editing market is poised for significant growth and Danaher's partnership with IGI places it at the forefront of this expansion. The focus on rare diseases, which are often overlooked due to the small patient populations, represents a strategic move to fill a niche market with high demand and low supply. The 'platform approach' concept, if successful, could set a new industry standard, making Danaher a key player in the gene-editing field.
Moreover, the collaboration's emphasis on addressing the entire spectrum of inborn errors of immunity (IEIs) with a unified approach could create a strong value proposition for healthcare providers and payers. By offering a comprehensive solution for a complex group of diseases, Danaher could see increased adoption rates of its technologies and solutions, driving market share and strengthening its position in the life sciences and diagnostics sectors.
- New collaborative research center based at University of
California ,Berkeley , plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses - Innovative model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract funding
- Nobel laureate Doudna and team to partner with Danaher to oversee center's translational and clinical research
Jennifer Doudna – Nobel laureate, CRISPR pioneer and founder of the IGI – will oversee work at the center at the IGI headquarters alongside Fyodor Urnov, IGI's Director of Technology and Translation and Director of the new Beacon. Both are professors at the University of
The collaboration, which enables a substantial new research program at IGI, is the largest Danaher Beacon to date. The Beacons program funds pioneering academic research with the goal of developing innovative technologies and applications for human health. Focus areas for Beacons include genomic medicines, precision diagnostics, next-generation biomanufacturing, human systems and data sciences.
Rainer Blair, President and CEO, Danaher, said: "CRISPR has enormous therapeutic promise, but there is no standard scientific or regulatory framework for how to get it to patients. To take on a challenge this big, we all need to work together with a sense of urgency across academia, industry, and government. We are thrilled to join forces with some of the finest scientific minds in gene editing at the IGI, bringing R&D and manufacturing talent, technology and expertise from across several of our operating companies in an effort to create transformative solutions for incredibly important but too-often underserved patient communities."
Doudna said: "Combining the strengths of the IGI and Danaher companies in this new center is a uniquely powerful way to deliver on the promise of CRISPR cures. We know how to get CRISPR molecules into the tissues where they need to be. We know the patient communities. And we have the world experts on these diseases on our team. What we need is a blueprint describing all the science and technology required to treat a person using CRISPR. Once that is achieved, I am convinced that CRISPR can become the standard of clinical care for many diseases."
As a first step, the Danaher-IGI Beacon aims to develop gene-editing therapies for two rare genetic disorders called "inborn errors of immunity" (IEIs), hemophagocytic lymphohistiocytosis (HLH) and Artemis-SCID. IEIs have several advantages that the parties believe make them amenable to the combined Danaher/IGI approach, including an extensive patient registry and a transplant-based route of administration that bypasses some key challenges in delivering CRISPR molecules to appropriate tissues.
Collectively, IEIs comprise some 500 distinct diseases that together affect many hundreds of thousands of people worldwide. Yet they are not currently the focus of any major gene-editing trials, largely because designing and testing therapies for each very small IEI patient population would be challenging, slow, and cost-prohibitive. Because of CRISPR's unique ability to be easily reprogrammed to address any gene mutation, the goal of the Beacon for CRISPR Cures is to develop a scalable platform approach that would enable a new medicine to be rapidly built, even for diseases beyond IEIs. The Beacon's goal is for the platform developed at the new center to be expandable across many IEIs, other rare diseases, or more common conditions that could be treated by editing a single specific gene.
Urnov said: "It is imperative that the public health impact of CRISPR expand rapidly beyond the initial, modest-in-size cohort of diseases currently pursued by the biotechnology sector. The unique nature of CRISPR makes it ideal for developing and deploying a platform capability for CRISPR cures on demand. Danaher and the IGI are in a unique position to join our respective strengths, build such a platform, and create a first-of-its-kind CRISPR cures 'cookbook' that can be used by any team wishing to take on other diseases."
Teaming up with leading clinicians focusing on IEIs at the University of
Danaher operating companies will provide tools, reagents, resources, and expertise to simplify preclinical and clinical development and develop new standards for safety and efficacy. Among them is Integrated DNA Technologies (IDT), which will contribute industry-leading capabilities in the synthesis, modification, purification, and quality control of CRISPR nucleases and guide RNA, drawing on its newly opened therapeutic oligonucleotide manufacturing facility. Aldevron, which has previously worked with IGI to advance the use of CRISPR-based gene editing in the brain, will also play a key role in the collaboration, alongside other Danaher operating companies including Cytiva, Beckman Coulter Life Sciences, Leica Biosystems, and Leica Microsystems.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, accelerating the power of science and technology to improve human health. Danaher partners closely with biopharmaceutical and healthcare customers to solve critical challenges affecting patients around the world. Powered by scientific excellence, innovation and a culture of continuous improvement, Danaher enables faster, more accurate diagnoses and reduces the time and cost it takes to discover, develop and deliver life-changing therapies sustainably and at scale. Danaher's 65,000 associates worldwide are not just accelerating the patient impact of today's science and technology—they are helping build a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
ABOUT THE INNOVATIVE GENOMICS INSTITUTE
The Innovative Genomics Institute is a joint effort between the Bay Area's leading scientific research institutions, UC Berkeley and UC San Francisco, with affiliates at UC Davis, Lawrence Berkeley National Laboratory, Lawrence Livermore National Laboratory, Gladstone Institutes, and other institutions. The IGI's diverse group of leading scientists have powerful interdisciplinary expertise. They conduct world-class research, driven by the real possibility of using genome engineering to treat human diseases, end hunger, and respond to climate change. In addition to our scientific efforts, the IGI is committed to advancing public understanding of genome engineering, providing resources for the broader community, and guiding the ethical use of these technologies.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including any statements regarding events or developments that Danaher believes or anticipates will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, potential future, adverse impacts on Danaher's business, results of operations and financial condition related to the COVID-19 pandemic, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions (including the pending acquisition of Abcam) and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of
Sources:
- "Introducing the CDC Rare Diseases Genomics and Precision Health Knowledge Base." April 4, 2019 by Muin J. Khoury and Wei Yu, Office of Public Health Genomics. Centers for Disease Control and Prevention.
View original content:SOURCE Danaher Corporation
FAQ
What is the purpose of the Danaher-IGI Beacon for CRISPR Cures?
Who will oversee the work at the IGI headquarters?
What is the goal of the Beacon for CRISPR Cures?
What are the focus areas for Danaher Beacons?
Who will provide tools, reagents, resources, and expertise to simplify preclinical and clinical development?
